PN is now considered one of the most important accomplishments in modern medicine—which makes it all the more distressing that unnecessary shortages are reducing its efficacy. “It breaks my heart,” says Dudrick, now a professor emeritus at Yale. “This is because big pharma isn’t making enough money on these components. It’s tragic. I just don’t know how they sleep at night.”
The IMSS has it bad, but this is worse. This is trickle-down economics for you.
This is what the powers that be in Mexico want.